DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.
Key Details
- 1FDA cleared DeepHealth's Prostate Suite, an AI platform for prostate MRI workflows.
- 2Tool provides AI assistance for lesion detection, risk assessment, segmentation, and PI-RADS reporting.
- 3Compatible with 11 fusion biopsy systems, integrating with radiologists' existing tools.
- 4Real-world use: detected 27% more lesions, reduced segmentation variability by 65%, and cut biopsy workflow times by 37%.
- 5RadNet also received CE Mark in Europe for Brain Health, Brain Age, and LumbarMR AI solutions.
- 6LumbarMR AI supports lumbar spine MRI analysis, added through Gleamer acquisition.
Why It Matters
FDA clearance signals increasing acceptance and integration of AI tools in radiology. These solutions may meaningfully improve cancer detection accuracy, workflow efficiency, and broader access to prostate and other disease screenings.
Source
Radiology Business
Related News
•Cardiovascular Business
AI Is Quietly Embedded in Cardiac Imaging Workflows
AI is now seamlessly integrated into cardiac imaging, often unnoticed by clinicians.
•Radiology Business
Radiology Dominates FDA AI Algorithm Clearances in 2026
Radiology accounted for 68 new FDA-cleared AI algorithms in early 2026, making up more than three-quarters of all AI clinical clearances.
•Radiology Business
AI Tool Dramatically Reduces Breast MRI Scan Time
A new AI-enabled MRI technique significantly speeds up breast imaging while enhancing image quality and tumor detection.